Melanoma antibody

Details for Product No. ABIN115270
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Reactivity
Human
(20)
Host
Mouse
(22)
Clonality (Clone)
Monoclonal ()
Application
Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
(16), (8), (3), (1), (1), (1), (1)
Pubmed 4 references available
Quantity 0.5 mL
Shipping to United States (Change)
Availability Will be delivered in 6 to 8 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN115270
577.50 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Pigmented melanoma metastases from lymphnodes(HMB45). Recombinant Human MART-1 protein(MART1). Recombinant Tyrosinase protein (Tyrosinase).
Clone Cocktail
Isotype Cocktail
Specificity The HMB45 clone reacts with a neuraminidase-sensitive oligosaccharide side chain of a glycoconjugate present in immature melanosomes. The combination of HMB45 and the MART-1 (cocktail) and Tyrosinase make this quadruple antibody cocktail a first-order pan melanoma screener. Cellular Localization: Cytoplasmic.
Purification Supernatant
Background The HMB45-reactive antigen is present in cutaneous melanocytes, prenatal and infantile retinal pigment epithelium and melanoma cells and is thought to be oncofetal in nature. This antibody has been shown to label the majority of melanomas. The MART-1/Melan A recognizes a protein of 18kDa, identified at MART-1 (Melanoma Antigen Recognized by T cells 1) or Melan-A. Melan-A is a useful addition to melanoma panels as it is apparently specific for melanocytic lesions. Studies have also shown that MART-1 is more sensitive than HMB45 when labeling metastatic melanomas. Tyrosinase is a key enzyme involved in the initial stages of melanin biosynthesis. Studies have shown Tyrosinase to be a more sensitive marker when compared to HMB45 and MART-1. It has also shown to label a higher percentage of desmoplastic melanomas than HMB45.
Alternate names: Melanoma marker
Research Area Cancer
Application Notes ELISA: To detect hSDF-1-beta by direct ELISA (using 100 l/well antibody solution) thisantibody can be used at a concentration of 0.15 - 0.30 ug/ml. Used in conjunction withcompatible secondary reagents, allows the detection of at least 0.2 ng/well of recombinanthSDF-1-beta. Western Blot: To detect hSDF-1-beta by Western Blot analysis this antibody can be used ata concentration of 0.1 - 0.2 ug/ml. Used in conjunction with compatible secondaryreagents the detection limit for recombinant hSDF-1-beta is 1.5 - 3.0 ng/lane, under eitherreducing or non-reducing conditions. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Buffer 10 mM citrate buffer, pH 6.0
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Expiry Date 12 months
General Kapur, Bigler, Skelly et al.: "Anti-melanoma monoclonal antibody HMB45 identifies an oncofetal glycoconjugate associated with immature melanosomes." in: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, Vol. 40, Issue 2, pp. 207-12, 1992 (PubMed).

Gown, Vogel, Hoak et al.: "Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes." in: The American journal of pathology, Vol. 123, Issue 2, pp. 195-203, 1986 (PubMed).

Chen, Stockert, Tsang et al.: "Immunophenotyping of melanomas for tyrosinase: implications for vaccine development." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, Issue 18, pp. 8125-9, 1995 (PubMed).

Kawakami, Battles, Kobayashi et al.: "Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1." in: Journal of immunological methods, Vol. 202, Issue 1, pp. 13-25, 1997 (PubMed).

Validation Images
Did you look for something else?
back to top